← Tier board·File·#019·Evidence reviewed Jun 2026Tweet
01 · the file

HGH Fragment 176 191.

F
Research-use-onlyIGF axis & growth-factor peptides
FHGH Fragment 176 191Verdict: Mostly animal evidenceHuman evidence: anecdotalStatus: Research-use-onlyReceiptsCalculatorReferences
💡 Explain this simply
What this is

HGH Fragment 176 191 is a research compound in the igf axis & growth-factor peptides.

Why people care

It draws interest for igf axis & growth-factor peptides.

What's actually supported

F-tier evidence: human evidence is limited; most support is preclinical.

What's not proven

General anti-aging / longevity; Human injury recovery; Muscle growth or fat loss claims.

What to be cautious about

Interesting on paper, but not a clinically proven option. The internet narrative is stronger than the human evidence.

What to compare next

Before you decide, compare HGH Fragment 176 191 with Human Growth Hormone, Aod 9604, Igf 1 Lr3. See all →

Research-onlyHuman-data limitedAnimal-data heavySafety unclearRegulatory friction high
What it is

HGH Fragment 176 191 is a research compound in the igf axis & growth-factor peptides.

What it does

Its biological effect is described in the mechanism section.

Why people use it

It draws interest for igf axis & growth-factor peptides.

Does it work?

F-tier evidence: human evidence is limited; most support is preclinical.

Bottom lineHGH Fragment 176 191 is F-tier: scientifically interesting in preclinical models, but human evidence is minimal and the online narrative tends to run ahead of it.
Evidence maturity
Anecdote
Mechanism
Animal
Early human
Clinical trials
Approved use

Currently sits at AnimalFindings come mainly from animal models, not people.

Online hypeLowvsActual evidenceEarlyGapBalanced
Key facts
  • HGH Fragment 176-191 is the C-terminal fragment of human growth hormone from which AOD-9604 is derived.
  • It is studied for fat metabolism/lipolysis while aiming to avoid GH's growth and IGF-1 effects.
  • Human evidence for meaningful fat-loss benefit is weak.
Safety & status
  • Not FDA-approved; research-only.
  • Long-term human safety and real-world efficacy are not established.
03 · evidence receipts

Marketing claim vs what the data actually shows. Tap a row for detail.

Claim audit for HGH Fragment 176 191 is in progress — common claims will be checked against sources here. Meanwhile, the real source corpus is in References.

04 · stack fit

Stack fit

Decision clarity: Unknown

Not enough indexed evidence to assess.

Best fitResearch interest in igf axis & growth-factor peptides.
Not a good fit forAnyone expecting proven human outcomes — the human evidence isn't there yet.
Evidence confidenceLow
Risk profileUnclear
Regulatory frictionHigh
Hype riskMedium

Stack verdict: Interesting on paper, but not a clinically proven option. The internet narrative is stronger than the human evidence.

Not proven for

HGH Fragment 176 191 is not established for:

General anti-aging / longevityHuman injury recoveryMuscle growth or fat loss claimsDisease treatmentAny use as a proven therapy

Tier ranking

F

A weighted evidence score of 30/100 places hgh-fragment-176-191 in F tier — based on published evidence, not popularity.

Weighted evidence score 30/100

Why not D: held back by human evidence, safety clarity, regulatory clarity, practical relevance.

What would move it up: Larger controlled human trials, clearer long-term safety, replicated findings, and regulatory progress.

What would move it down: Failed confirmatory trials, new safety signals, or evidence that popular claims don't translate.

Hype vs evidence (shown separately — does not affect the tier)
Internet hype: LowEvidence strength: EarlyRisk of overstatement: Medium
05 · safety / status
Evidence gap alert. Most support comes from animal, cell, or early research — high-quality human clinical evidence is limited.
Regulatory alert. This compound is not FDA-approved for the uses commonly discussed online.
Safety alert. Long-term human safety is not well established. Quality and purity from non-pharmaceutical sources is an additional risk.
Can it legally be used?Research-use-only
EMA / internationalVerify by region
Sport (WADA)Check the current WADA prohibited list
Known side effectsNot well characterized in humans
Biggest unknownsLong-term safety, broad off-label use, rare events
Main cautionResearch-only; human evidence limited; sourcing & purity risk
What we know
  • HGH Fragment 176 191 is not FDA-approved for human use; it is discussed in a research context.
  • It belongs to the IGF axis & growth-factor peptides class.
What we don't know
  • Whether observed effects reliably translate to humans at large.
  • Long-term safety in healthy users, and full drug-interaction risk.
  • Optimal studied parameters outside any approved indication.
  • Claim-by-claim verdicts — these are authored against verified sources and shown when complete.
  • Quality and purity of material from non-pharmaceutical sources.
Caution if you're researching
Research-only compoundsCompetitive sports (anti-doping)Diabetes / glucose regulationPregnancy / fertility

This is not medical advice. These are areas where professional guidance and better evidence matter most.

06 · compare before you decide

See it next to its closest alternatives.

HGH Fragment 176 191 vs Human Growth HormoneHGH Fragment 176 191 vs Aod 9604HGH Fragment 176 191 vs Igf 1 Lr3HGH Fragment 176 191 vs Peg MgfHGH Fragment 176 191 vs Follistatin 344Build a comparison →
07 · the read

Full brief

A deeper, chapter-by-chapter research briefing. Tap any chapter to expand.

In this brief
  1. What it is
  2. The preclinical evidence lane
  3. Why Preliminary, and not higher or lower
  4. Proven lane vs speculative lane
  5. What people report
  6. Regulatory status
  7. What changed recently
01What it is

Simple takeaway: HGH Fragment 176 191 is a research compound in the igf axis & growth-factor peptides.

Growth-hormone, IGF-axis, and related growth-factor peptides and fragments. It is not approved for human use; it is discussed here in a research context only.

03The preclinical evidence lane

Simple takeaway: Support is mainly preclinical; 0 registered trials and 0 sources indexed.

The most defensible evidence comes from animal and mechanistic models. Human clinical evidence is limited.

What this does not prove. Preclinical or early-stage evidence does not establish reliable human outcomes.
04Why Preliminary, and not higher or lower

Simple takeaway: Composite maturity 1.8/5.

What holds it back: human evidence, safety clarity, regulatory clarity, practical relevance. What supports its placement: its overall evidence profile. Stronger human trials, clearer long-term safety data, and regulatory progress would move it up; a safety signal or failure to replicate would move it down.

05Proven lane vs speculative lane

Simple takeaway: The research interest is real; most popular claims remain speculative.

What's supported is the preclinical/mechanistic research. What's speculative is the broad human benefit frequently claimed online, which the indexed human evidence does not establish.

06What people report

Simple takeaway: Community reports are not clinical evidence.

Online reports can surface expectation patterns and possible safety signals, but they are shaped by placebo effects, selection bias, confounders, and uncertain product quality and sourcing. We don't treat anecdotes as proof and we don't publish dosing or protocols.

What this does not prove. Anecdotes cannot establish efficacy or safety.
07Regulatory status

Simple takeaway: Research-use-only

Not approved by the FDA for human use; studied in research contexts. Regulatory status can change and differs by country; several peptides are also prohibited in sport (WADA). Verify current status before relying on it.

08What changed recently

Simple takeaway: No major evidence-changing update was identified in this review window.

The current profile reflects the existing body of indexed evidence. Material changes — new trials, approvals, or safety findings — are noted here when an editor logs them.

0 of 7 brief sections read
08 · community call

How the community sees this vs the evidence.

Your call on F-tier?

Evidence tier is F. Do you agree?

Community votes reflect user perception, not scientific proof — the evidence tier comes from our Research Maturity Index. Aggregate community sentiment will appear here once enough votes are collected.

Aggregate community sentiment will appear here once enough votes are in — we don't show invented numbers.

09 · follow updates
Follow updates on HGH Fragment 176 191

Get notified when new studies, safety updates, regulatory changes, or the tier ranking change.

· New human study· Safety update· Regulatory change· Tier change· New claim check
10 · FAQ

FAQs

Is HGH Fragment 176 191 FDA-approved?

No. HGH Fragment 176 191 is not FDA-approved for the uses commonly discussed online. Not approved by the FDA for human use; studied in research contexts.

What is HGH Fragment 176 191 studied for?

HGH Fragment 176 191 is studied mainly for igf axis & growth-factor peptides. Growth-hormone, IGF-axis, and related growth-factor peptides and fragments.

What does the research say about HGH Fragment 176 191?

Mostly animal evidence. Human data is limited; most support comes from preclinical research.

Is HGH Fragment 176 191 safe?

Long-term human safety is not well established for HGH Fragment 176 191. Quality and purity from non-pharmaceutical sources is an added risk.

🧮 Reconstitution calculator (educational)

Educational reconstitution math from your own values — not medical advice or a dose recommendation. Open the full calculator →

Medication (optional — 30+ in library)
Peptide in vial (mg)
Reconstitution water (mL)
Target amount per draw
Syringe
Draw to
10
units
Volume to draw
0.1
mL
At this amount
20
draws / vial
After one draw
4.75
mg left
Syringe · draw to 10 of 100 units
0
10
20
30
40
50
60
70
80
90
100

Each unit on a 100u · 1.0 mL syringe ≈ 25 mcg of this solution.

Concentration
2.5
mg / mL
Concentration
2,500
mcg / mL
Per U-100 unit
25
mcg / unit
Show the math
5 mg × 1000 = 5,000 mcg in the vial
2 mL × 100 = 200 U-100 units of liquid
5,000 mcg ÷ 200 units = 25 mcg per unit
250 mcg ÷ 25 mcg/unit = 10 units
10 units ÷ 100 = 0.1 mL
5,000 mcg ÷ 250 mcg = 20 draws per vial
Compare reconstitution volumes (5mg vial)
Water
mcg / unit
units for 250mcg
1 mL505
2 mL2510
2.5 mL2012.5
3 mL16.6715
5 mL1025

More water → lower concentration → more units for the same amount.

Tweet
📩 Email yourself this setup

Get the vial, water, target, and 10-unit draw sent to your inbox so it's easy to reference — and follow when the evidence changes. Free, no account.

Keep exploring
Compare nextHGH Fragment 176 191 vs Human Growth HormoneSee the evidence side by side.ToolConcentration calculatorHow vial size & water change concentration.
Explore related
Related compounds
Human Growth HormoneSAOD 9604DIGF 1 LR3FPEG MGFFFollistatin 344F
Class
IGF axis & growth-factor peptides
Share this fileTweet

← Back to the full database

Research reference only. Not medical advice, treatment instructions, or a purchase recommendation. Consult a licensed professional.

The all-in-one peptide app

Stop reading, start tracking.

PepCue logs your doses, runs the vial math, counts your vials, and keeps the whole protocol in one place. It replaces the spreadsheet, the calculator, and the sticky notes.

  • Dose logging
  • Reconstitution math
  • Smart reminders
  • Vial & cost tracking
iPhone · free to start
HGH Fragment 176 191: Profile In Progress